After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology "The new products we have planned for 2024 will take 10x to ...
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms In this study, "High resolution mapping ...
Citi analyst Patrick B Donnelly has maintained their bullish stance on TXG stock, giving a Buy rating today. Patrick B Donnelly has given his Buy rating due to a combination of factors. In 3Q23, 10x ...
Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management credited continued momentum in single cell and ...
The 10X Genomics Xenium Analyzer will support true single cell spatial transcriptomics on fresh frozen or fixed tissue samples. You can characterize 100s to 1000s of RNAs in cells and tissues using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results